Bristol Myers Squibb says Phase 3 ALOFT-IPF trial of admilparant met primary endpoint

Bristol Myers Squibb said its Phase 3 ALOFT-IPF trial of admilparant met its primary endpoint. The 60 mg twice-daily dose significantly improved change in forced vital capacity at Week 52 versus placebo.

Detected & updated continuously · Source: Nebula